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Background/aim: We aimed to evaluate the prevalence of sarcopenia and associated outcomes in patients with chronic obstructive
pulmonary disease (COPD).
Materials and methods: This cross-sectional study was performed on 219 patients aged 50 years and over who were diagnosed with
chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines. The study included 196 (89.5%) male and 23 (10.5%) female patients. The mean age of the patients was 66.9 ± 10.1 years. To
diagnose sarcopenia, muscle function was determined by a gait speed test. Muscle strength was assessed with a hand dynamometer and
muscle mass was measured with a bioelectrical impedance analysis device. Pulmonary function tests and six-min walking tests were
also performed. The modified Medical Research Council (mMRC) dyspnoea scale was used to evaluate all the participants. Our sample
consisted of sarcopenic patients at different stages (17 presarcopenic patients (7.8%), 32 patients with sarcopenia (14.6%), 65 patients
with severe sarcopenia (29.7%), and 105 nonsarcopenic patients (47.9%).
Results: Sarcopenia was significantly associated with age, BODE (body mass index (BMI), airflow obstruction, dyspnoea, and exercise
capacity) index, GOLD spirometric classification, mMRC dyspnoea scale score, BMI, and educational status. Sarcopenia in COPD
patients was firmly related to the severity of the disease and its prognosis. The prevalence of sarcopenia increased in severe and very
severe COPD cases. The dyspnoea score was higher, and exercise capacities were lower in sarcopenic patients.
Conclusions: Sarcopenia in COPD patients was closely related to the severity of COPD and a negative prognosis. The frequency of
sarcopenia increased in severe and very severe COPD cases. Dyspnoea scores were higher and exercise capacities were lower in patients
with sarcopenia. In patients with COPD, a diagnosis of sarcopenia should be considered, and preventive measures should be taken
before irreversible changes develop.
Key words: Chronic obstructive pulmonary disease, dyspnoea, sarcopenia

1. Introduction
The current definition of sarcopenia describes the condition
as one which involves the loss of muscle capacity, muscle mass,
and functional capacity [1]. It is assumed that sarcopenia is
a consequence of hormonal and immunological changes
that occur on account of ageing. Nevertheless, recent studies
have shown that chronic inflammatory disorders also cause
sarcopenia [2]. Studies have shown that the loss of muscle
increases in individuals with chronic inflammatory diseases
due to increased levels of proinflammatory cytokines,
particularly TNF-α and IL-6.
Chronic obstructive pulmonary disease (COPD)
develops as a result of inflammatory processes working
against harmful gases and inhaled particles, especially
cigarette smoke. The systemic effects of the inflammatory

process that occurs in the lungs can explain the close
relationship between COPD and comorbidities [3]. Acute
inflammation in the lung periphery leads to an increase in
acute phase proteins such as C-reactive protein, fibrinogen,
serum amyloid A, and surfactant protein D by driving the
transmission of cytokines such as TNF-α, IL-1β, and IL-6
into systemic circulation. This increase becomes more
evident through exacerbations. Systemic inflammation
causes skeletal muscle atrophy and cachexia, initiates
comorbid conditions, and increases their severity.
There are significant changes in muscle strength,
morphology, mass, oxidative capacity, and resistance
in severe and very severe COPD cases. At this point,
muscles contract slowly but get tired quickly, resulting
in early lactic acidosis and reduced exercise capacity.
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Prolonged immobilisation, disuse of muscles, hypoxemia,
hypercapnia, acidosis, malnutrition, and systemic steroid
use are also responsible for functional and structural
changes in muscles as well as systemic inflammation. Loss
of muscle strength and endurance results in fatigue, reduced
quality of life, and reduced exercise capacity. One study
has emphasised that muscle weakness is closely related
to morbidity and mortality [4]. Consequently, the loss
of muscle mass, function, and strength (in another word,
‘sarcopenia’) occurs as a result of the systemic inflammatory
effects of COPD. Thus, in this study, we aimed to evaluate
the prevalence of sarcopenia and the associated outcomes
in COPD patients.
2. Materials and methods
This cross-sectional study was performed on 219 patients
aged 50 years and over who were diagnosed with COPD
according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines. The study was conducted
at Necmettin Erbakan University, Meram Faculty of
Medicine between October 2017 and January 2018. Ethical
approval was obtained from the Ethical Committee of
Necmettin Erbakan University (approval date: 16.03.2018;
approval number: 2018/1277). The study included 219
COPD patients (196 males: 89.5% ; 23 females: 10.5%) with
an average age of 66.9 ± 10.1 years.
2.1. Anthropometric measurements
The height, body weight, and waist circumference of each
participant were measured and recorded. Height was
measured to the nearest 0.1 cm using a standard stadiometer
(Seca GmbH & Co. KG., Hamburg, Germany) with the
participant wearing no shoes. Weight, body fat percentage,
muscle mass, basal metabolism, and the amount of visceral
fat of all the participants were measured with a bioelectrical
impedance analysis (BIA) device. Body mass index (BMI)
was calculated with the formula BMI = weight (kg) /
height (m2). Skinfold thickness was measured with a digital
skinfold analyser device. All the patients were measured in
a standing position. The measurements were performed
vertically at a distance of 2 cm to the right of the umbilicus.
2.2. COPD-related parameters
The patients were asked about the duration of their COPD
diagnosis, the number of exacerbations they had in the
previous year, the medications they used, and whether they
had any comorbidities. Additionally, the participants were
asked whether they had ever smoked. Then, the patients
were divided into three groups: ‘never smokers’, ‘current
smokers’, and ‘former smokers’. The total number of packs
smoked per year was calculated for each patient.
2.3. Dyspnoea scales
The dyspnoea levels of the participants were graded from 0
to 4 using the modified British Medical Research Council
(mMRC) scale.

2.4. BODE index
The BODE index was calculated with the sum of the scores
obtained as a result of the measurement of four factors: BMI
(B), airflow obstruction (O), dyspnoea (D), and exercise
capacity (E).
2.5. Pulmonary function tests
Pulmonary function tests were performed in the Respiratory
Function Laboratory in the Chest Diseases Department of
Necmettin Erbakan University Meram Faculty of Medicine.
Pulmonary function tests were performed according to the
ATS/ERS criteria using standardised equipment (EasyOne
Pro® LAB, ndd Medical Technologies, Inc., Andover, MA,
USA) [5].
2.6. Diagnosis of sarcopenia
After testing muscle mass, gait speed and handgrip strength,
the patients were divided into four groups according to the
European Working Group on Sarcopenia in Older People
(EWGSOP) stages, including ‘presarcopenia’, ‘sarcopenia’,
‘severe sarcopenia’ and ‘nonsarcopenia’. Presarcopenia is
defined as low muscle mass with normal muscle strength
and physical performance; sarcopenia is defined as low
muscle mass with low muscle strength or low physical
performance; and severe sarcopenia occurs when all
three criteria of sarcopenia (low muscle mass, low muscle
strength, and low physical performance) are met.
2.6.1. Evaluation of muscle strength
The handgrip strength measurement of the patients was
performed with the Takei grip strength dynamometer.
Three consecutive measurements were performed on the
dominant hand, and the highest value was recorded for
each patient.
2.6.2. Evaluation of muscle mass
The body composition of each patient was determined with
the BIA method using the Tanita InnerScan BC-532 Body
Composition Monitor (Tokyo, Japan). The measurements
were taken while the patients were fasting with no urge to
urinate and wearing no metal items (e.g., necklace, ring, or
watch). Muscle mass was automatically calculated by the
BIA device. Additionally, the BIA device also measured lean
body mass (LBM). Skeletal muscle mass (SMM) (kg) was
calculated with the formula of [0.566 ×* LBM] [6]. Then, the
skeletal muscle mass index (SMMI) (kg/m2) was calculated
by dividing the SMM by the square of the patient’s height.
A receiver operating characteristics (ROC) analysis was
performed to determine the cut-off values of the SMMI.
Values less than 9.84 kg/m2 for females and under 10.37 kg/
m2 for males were considered to be indicative of low muscle
mass (Figure 1, 2).
2.6.3. Evaluation of gait speed
The subjects were instructed to walk a distance of 6 metres
in their regular walking style in order to determine their
gait speed (6-MWT). This walking time was measured
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Figure 1. ROC curve and AUC for male patients’ SMMI (AUC =
0.652, P = 0.005; 65.4% sensitivity and 65.2% specificity). AUC =
Area under the curve, SMMI = Skeletal muscle mass index, ROC
= Receiver operating characteristic curve.

Figure 2. ROC curve and AUC for female patients’ SMMI (AUC
= 0.542, P = 0.005; 50.0% sensitivity and 46.7% specificity). AUC
= Area under the curve, SMMI = Skeletal muscle mass index,
ROC = Receiver operating characteristic curve.

using a digital stopwatch. At the start, each participant
was located just behind the starting point. After the entire
body exceeded the starting point, the time measurement
started. The time measurement terminated when the entire
body crossed the end point. The speed was calculated as
the distance divided by the walking time. The gait speed
was measured twice, and the mean of the two trials was
used. According to the EWGSOP diagnostic algorithm,
the patients with a gait speed lower than 0.8 m/s were
considered to have a low gait speed [7].
2.7. Statistical analysis
Statistical analysis was performed with the Statistical
Package for the Social Sciences software (SPSS version
20, IBM Corp., Armonk, NY, USA). The tables show the
mean and standard deviation (SD) values as descriptive
statistics of the continuous variables, and the frequency
(χ2) and percentage (p) values for the descriptive statistics
of the categorical data. The independent samples t-test and
one-way ANOVA tests were used for the comparison of the
quantitative data, and a chi-squared test was performed
to compare the categorical data. The effects of factors
associated with sarcopenia were evaluated using univariate
and multivariate regression analysis. A ROC analysis was
performed to determine the male and female cut-off values
of skeletal muscle mass index (SMMI) and muscle strength.
The results were evaluated with a confidence interval of
95%, and the level of significance, P, was set at 0.05.

3. Results
3.1. Sociodemographic characteristics of patients:
With respect to the ages of the patients, 55 (25.2%) were
50–59 years of age, 76 patients (34.7%) were 60–69, 59
patients (26.9%) were 70–79, and 29 patients (13.2%)
were ≥80. Of the participants, 49 (22.4%) were single
and 170 (77.6%) were married. The patients were divided
into 5 groups according to their educational status: 40
participants (18.3%) were illiterate, 134 participants
(61.2%) had completed primary school, 26 participants
(11.9%) had completed secondary school, 10 participants
(4.6%) were high school graduates, and 9 participants
(4%) were university graduates. The sociodemographic
characteristics of the participants are shown in Table 1.
As to the status of tobacco use, 26 (11.9%) participants
reported that they were nonsmokers, while 42 (19.2%)
were current smokers and 151 (68.9) were former smokers.
The duration of smoking was 57.8 ± 29.9 packs/year.
When the patients were evaluated for the presence of any
additional diseases, it was determined that 37 (16.9%) had
diabetes mellitus, 74 (33.1%) had hypertension, 72 (32.9%)
had coronary artery disease, and 29 (13.1%) had benign
prostatic hyperplasia.
3.2. Prevalence of sarcopenia:
The cut-off values for muscle strength were determined
for male and female patients via the ROC analysis. The
values under 14.25 kilograms for females and 28.75
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kilograms for males were considered to be indicative of
low muscle strength. The ROC analyses were performed
for grip strength by using the cut-off values that predicted
a gait speed of <0.8 m/s; for calf circumference, the cut-off
values that predicted low muscle mass were used [8]. Table
2 shows the relationship between sarcopenia and some
other parameters. Sarcopenic patients were significantly
older, and their BMI was also lower. In sarcopenic patients,
muscle mass, fat ratio, and skinfold thickness were
significantly lower. Our sample consisted of sarcopenic
patients at different stages (17 presarcopenic patients
(7.8%), 32 patients with sarcopenia (14.6%), 65 patients

with severe sarcopenia (29.7%), and 105 nonsarcopenic
patients (47.9%). While comparing all the parameters
in our study, the patients in the stages of presarcopenia,
sarcopenia, and severe sarcopenia were combined and
divided into two main groups as those who were sarcopenic
and those who were nonsarcopenic. Table 3 indicates
the relationship between sarcopenia and the COPD
findings. The percentage of FEV1 was significantly lower
in the sarcopenic patients compared to the nonsarcopenic
patients, and the number of hospitalisations in one year
was significantly higher for sarcopenic patients as well. As
the BODE index, GOLD stage, and mMRC dyspnoea scale

Table 1. The sociodemographic characteristics of the participants.
Sociodemographic characteristics

No sarcopenia

Sarcopenia

N

%

n

%

50–59

32

58.2

23

41.8

60–69

44

57.9

32

42.1

70–79

22

37.3

37

62.7

≥80 years

7

24.1

22

75.9

Female

12

52.2

11

47.8

Male

93

47.4

103

52.6

Single

22

44.9

27

55.1

Married

83

48.8

87

51.2

Illiterate and primary school graduated

77

44.3

97

55.7

Secondary school and upper graduated

28

62.2

17

37.8

χ2

p

15.016

0.002

0.043

0.835

0.104

0.747

3.934

0.047

Age groups

Sex

Marital status

Education status

Table 2. The relationship between sarcopenia and some other parameters.
No sarcopenia

Sarcopenia

Mean ± SD

Mean ± SD

Age ( year )

64.6 ± 9.1

Waist circumference (cm)
Weight (kg)

T

P

69.1 ± 10.4

3.366

0.001

110.9 ± 15.8

93.7 ± 13.2

–8.736

< 0.001

85.4 ± 14.7

62.9 ± 12.1

–12.363

< 0.001

BMI ( kg/m )

30.2 ± 5.3

22.7 ± 4.2

–11.636

< 0.001

Muscle mass ( kg )

58.4 ± 7.6

44.2 ± 5.8

–15.644

< 0.001

Fat rate ( % )

26.8 ± 10.4

23.9 ± 10.3

–1.995

0.047

Visceral fat ( kg )

15.1 ± 11.6

10.7 ± 4.8

–4.529

< 0.001

SFT ( mm )

26.3 ± 8.9

19.2 ± 9.1

–5.791

< 0.001

2

BMI: Body mass index, SFT: Skin-fold thickness.
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Table 3. The relationship between sarcopenia and COPD findings.
No sarcopenia

Sarcopenia

Mean ± SD

Mean ± SD

FEV1%

47.6 ± 18.5

FEV1 - L
FVC%

T

P

41.5 ± 16.9

–2.560

0.011

1.4 ± 0.6

1.1 ± 0.5

–3.735

< 0.001

57.0 ± 19.8

52.9 ± 18.8

–1.555

0.121

FVC - L

2.1 ± 0.8

1.8 ± 0.7

–2.819

0.005

FEV1 / FVC

63.2 ± 7.4

59.2 ± 8.9

–3.654

< 0.001

mMRC

1.56 ± 1.1

2.3 ± 1.0

5.035

< 0.001

BODE index

3.5 ± 2.7

5.4 ± 2.7

5.140

< 0.001

Diagnosis time (year)

6.9 ± 7.5

7.4 ± 6.7

0.417

0.677

Hospitalizations / year

1.55 ± 2.0

3.25 ± 5.1

3.160

0.002

6-MWT (meter)

308.5 ± 123.4

237.9 ± 105.7

–4.555

< 0.001

Table 4. Multivariate logistic regression results.
Variables

Adjusted OR (Sarcopenia
versus no sarcopenia)

95% CI

P

Age groups (year)
50–59

1

60–69

0.759

0.308– 1.865

0.548

70–79

2.327

0.811– 6.676

0.116

≥ 80 years

2.611

0.657– 10.379

0.173

GOLD spirometric classification
Stage 1 FEV1 ≥ 80

1

Stage 3 FEV1 30– 49

Stage 2 FEV1 50– 79

3.909

0.426– 35.848

0.228

2.666

0.267– 26.634

0.404

Stage 4 FEV1 < 30

3.740

0.318– 43.988

0.294

BODE 0– 2

1

BODE 3– 4

5.520

1.496– 20.362

0.010

BODE 5– 6

11.021

1.560– 77.840

0.016

BODE 7– 10

34.392

4.492– 263.308

0.001

0.754– 14.868

0.112

12.389– 106.594

< 0.001

BODE classification

Mmrc
mMRC 0–1

1

mMRC ≥ 2

3.347

BMI (kg/m2)
BMI ≥ 30

1

BMI < 30

36.340

scores increased, the incidence of sarcopenia increased
significantly.
Univariate logistic regression analysis was performed
with the possible variables that may be associated with
sarcopenia. Patient age, BODE index group, GOLD

1274

spirometric classification, mMRC dyspnoea scale
score, educational status, and BMI were included in the
multivariate model because they were related to sarcopenia
to a statistically significant extent (P < 0.05). The
multivariate logistic regression results are shown in Table
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Table 5. Correlation between sarcopenia and some parameters.
1
1.Muscle mass index
2.Gait speed
3.Handgrip strength
4.FEV1 %
5.FEV1-L
6.mMRC
7.BODE
8.6-MWT (meter)

r
P

2

3

4

5

6

7

8

1

r

0.232**

P

0.000

r

0.350**

0.553**

P

0.000

0.000

r

0.131

0.539**

0.260**

P

0.052

0.000

0.000

r

0.223**

0.603**

0.416**

0.857**

P

0.000

0.000

0.000

0.000

r

–0.255**

–0.799**

–0.537**

–0.600*

–0.637*

P

0.000

0.000

0.000

0.000

0.000

r

–0.249**

–0.837**

–0.529**

–0.722**

–0.724**

0.899**

P

0.000

0.000

0.000

0.000

0.000

0.000

r

0.229**

0.970**

0.550**

0.543**

0.603**

–0.818**

–0.858**

P

0.001

0.000

0.000

0.000

0.001

0.000

0.000

1
1
1
1
1
1
1

** Correlation is significant at the 0.01 level (2-tailed).

4, and Table 5 shows the correlations between sarcopenia
and some of the relevant parameters. The probability of
sarcopenia in patients 80 years of age and over was 2611
times higher than for those in the 50–59 age group [OR
= 2611, 95% CI; (0.657–10.379), P = 0.173]. Those with
FEV1 < 30 were 3740 times more likely to have sarcopenia
than those with FEV1 ≥ 80 [OR = 3740, 95% CI; (0.318–3.988), P = 0.294]. The likelihood of sarcopenia for those
with a BODE index of 7–10 was 34,392 times higher than
those with a BODE index of 0–2 [OR = 34,392, 95% CI;
(4,422–21,160), P = 0.001]. The probability of sarcopenia
for those in the group with mMRC dyspnoea scale scores
>2 was 3347 times higher than it was for those in the group
with mMRC 0–1 [OR = 3347, 95% CI; (0.754–14.868), P
= 0.112]. The nonprimary and primary school graduates
were 1409 times more likely to have sarcopenia than it was
for those who were secondary school graduates or had
higher levels of education.
When assessing the linear regression analysis of the
gait speed and the BODE index for sarcopenic and nonsarcopenic patients, it was found that 70.1% of the decrease
in gait speed could be attributed to the BODE index (R2 =
0.701, P < 0.001) (Figure 3).
4. Discussion
This project is a pioneering study in Turkey insofar as
it examines sarcopenia in COPD patients using the
EWGSOP criteria. Based on the results of this study, body

composition and sarcopenia in COPD patients appear
to be associated with the severity and prognosis of the
disease. The overall prevalence of sarcopenia in 219 COPD
patients was found to be 29.7% in our study, and this rate
was in accordance with the current literature, in which the
reported prevalence is 20%–40%.
In review of other research on related issues, Costa
et al. used a dual-energy X-ray absorptiometry (DXA)
for the assessment of the body composition of 96 COPD
patients. For the purpose of the densitometric diagnosis
of sarcopenia, they used the skeletal muscle index (SMI)
calculated as [SMI = ALM/height2 (kg/m2)]. They observed
sarcopenia in 36 (39.6%) of the patients [9]. Similarly,,
Limpawattana et al. used DXA to assess 121 COPD patients
in their study performed in Southeast Asia. The SMI was
calculated as ALM/height2. They subjected the patients
to a handgrip strength test to measure muscle functions
and a 6-MWT. At the end of the study, the prevalence of
sarcopenia was determined to be 39.6% [10].
For the diagnosis of sarcopenia in this study,
muscle mass was measured with the BIA device, and
muscle strength was assessed by using a hand-held
dynamometer. A 6-MWT was performed to evaluate
physical performance. In our study, the probability of
having sarcopenia among those 80 years of age and over
was 2.6 times higher than the corresponding rate among
those in the 50–59 age group. Costa et al. declared that
the prevalence of sarcopenia was 2.8 times higher in those
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Figure 3. Regression analyses of gait speed and BODE index.

over 67 years, and this rate is closely similar to our results
[9]. The prevalence of sarcopenia in some studies has been
reported to be 5%–13% for those in the 60–70 age group,
11%–50% for those over 80 years of age, and 8%–40% for
those over 60 years of age [11,12]. Akin et al. found that
the prevalence of sarcopenia was 63.4% in the geriatric
population [13]. In another study conducted on elderly
male patients staying in nursing homes, Bahat et al. found
that the prevalence of sarcopenia was 85.4% [14].
In our sample of COPD patients, we found that an
increased likelihood of being diagnosed with sarcopenia
was correlated with an increased BODE index. In fact,
the prevalence of sarcopenia in patients who had a
BODE index of 0–7 was 34.4 times higher than the rate
of patients who had a BODE index of 0–2. Currently,
studies on the relationship between sarcopenia and the
BODE index in COPD patients are scarce. Nevertheless,
two different studies established that there was a strong
relationship between the BODE index and the prevalence
of sarcopenia [9,15]. Another study suggested that the
BODE index was significantly associated with sarcopenia,
and that sarcopenia was more prevalent among patients
with a worse prognosis [16]. In any event, the BODE
index is an important tool for evaluating the prognosis of
sarcopenia and predicting mortality in COPD patients.
The BODE index can also be used to determine the risk of
hospitalisation for patients with COPD.
When the sarcopenia and GOLD spirometric
classification were considered together, a significant
association was demonstrated between the presence of
sarcopenia and disease severity according to the GOLD
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staging. Jones et al. also reported on this association
in their own study, indicating that the prevalence of
sarcopenia increased with spirometrically-defined disease
severity [17]. Furthermore, in our study, the prevalence
of sarcopenia in patients who had FEV1 values of <30 was
3.75 times higher than those who had FEV1 values of ≥80.
A significant decrease was also observed in the FEV1 value
in sarcopenics and severe sarcopenics in another study
[18]. Similarly, Ischaki et al. showed that an increased
loss of lean muscle leads to an increase in the severity of
disease in COPD patients and, therefore, an increase in the
GOLD stage [19].
Dyspnoea is one of the most important factors reducing
the quality of life and limiting daily life activities in COPD
patients [20]. In our study, we examined the relationship
between sarcopenia and mMRC dyspnoea scores. Our
results showed that the prevalence of sarcopenia increased
as the dyspnoea scores increased. The results obtained
from other studies on this subject were in line with our
results [17,21]. In another study, it was reported that a high
mMRC score was also an indicator of poor lung capacity,
and this was associated with sarcopenia [10]. Another
study identified a correlation between mMRC dyspnoea
scale scores and handgrip strength [21]. Since the
sarcopenic patients of our study also had a low handgrip
strength, similar results were obtained.
It should be noted that the education level of our patients
was low. While illiterate and primary school graduates
comprised 79.5% of the sample, only 4% of the patients
were university graduates. The findings with respect to this
composition were consistent with other studies associating
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the levels of education and COPD [22]. Additionally, we
examined the relationship between educational level and
sarcopenia. As far as it is known, there is no study in the
literature on the association between educational level
and the prevalence of sarcopenia in COPD patients. In
our study, it was determined that as the level of education
decreased, the prevalence of sarcopenia increased.
The relationship between sarcopenia and BMI was also
examined in our study. The prevalence of sarcopenia was
higher in the nonobese group. In other words, sarcopenic
patients were weaker and generally underweight.
Additionally, some level of weakness, lower handgrip
strength, and lower waist circumference were expected of
sarcopenic patients, and these results were supported by
previous studies. A low BMI (<21 kg/m2) is indicative of
a poor prognosis on the BODE index, which is a common
scoring system used to determine the prognosis of COPD
[23]. Accordingly, sarcopenia is closely related to the
BODE index, which also predicts a higher risk of mortality.
However, the loss of muscle may increase in time, and
lost muscle may be replaced by fat stores. Thus, a COPD
patient may well have lost considerable lean body mass
(LBM) but may have extra fat stores, resulting in an overall
normal BMI [24,25]. In another study, it was reported that
the loss of skeletal muscle mass is crucially important in
the prognosis of COPD patients [4]. A Brazilian study
showed that the loss of LBM is associated with a lower
BMI in patients with COPD. However, the authors did not
find BMI to be associated with COPD severity or a worse
prognosis [9]. Nevertheless, some studies have shown that
the loss of muscle can reduce survival by up to 50% [25].
This indicates the importance of pulmonary rehabilitation
and physical activity in COPD patients.
We have mentioned that the BMI of sarcopenics is
low. However, it should not be forgotten that there is a
description of what is referred to as ‘sarcopenic obesity’
in the literature. This means that a patient who has a high
BMI and a high waist and hip circumference may also
suffer from sarcopenia. In some studies, patients with
sarcopenia were found to be more overweight and had
higher BMIs and waist circumferences than those without
sarcopenia [26].
In our study, muscle mass index, handgrip strength,
and gait speed were significantly correlated with the results
of the mMRC dyspnoea scale, BODE index, 6-MWT
and pulmonary function tests. In a study performed by
Byun et al., low handgrip strength and low SMMI were
significantly correlated with mMRC dyspnoea scale scores,
COPD Assessment Test (CAT) scores, and 6-MWT times
[21] . In a multicentre study, handgrip strength was also
found to be significantly correlated with the prognosis of
patients with COPD [27]. After the age of 70, a decrease

in gait speed and handgrip strength was found to be faster
than the loss of muscle mass [28,29]. As a result of these
findings, it is clear that the measurements of handgrip
strength can provide critical prognostic information about
COPD patients.
In a study performed with COPD patients in South
Korea, it was reported that sarcopenic patients had shorter
6-MWT times [21] and in other studies, sarcopenia and
shorter 6-MWT times were also associated [10,17]. In
accordance with these findings, we found that the 6-MWT
results of the sarcopenic patients were lower than those
of nonsarcopenic patients. Ultimately, the loss of muscle
mass in COPD patients leads to a decrease in exercise
capacity. This also leads to a decrease in the quality of life
indices and an increase in exacerbation frequency and
mortality [30].
Studies have shown that smoking causes loss of muscle
mass by increasing protein catabolism [31]. In our study, no
relationship was found between smoking and sarcopenia.
Studies conducted on patients with COPD showed that
smoking was only associated with a loss of muscle mass,
yet it was not related to handgrip strength and gait speed,
which are the diagnostic parameters of sarcopenia [32].
There are continued discussions in the literature on this
subject, with one study claiming that smoking might only
be a risk factor for sarcopenia with other cytokines [7].
However, it should be kept in mind that smoking is the
most important risk factor for COPD, and it is the most
important trigger of the systemic inflammatory effect of
COPD.
In our study, skinfold thickness measurements were
lower in the sarcopenic group than in the nonsarcopenic
group. In the current literature, there is no relevant study
on sarcopenia and skinfold thickness among COPD
patients. However, one study performed by Akin et al.
in Turkey to determine the cut-off value of sarcopenia in
elderly Turkish people found that skinfold thickness was
significantly lower in the sarcopenia group [13].
Since we performed our study in a tertiary hospital, our
study population had more comorbidities and increased
disease severity.
5. Limitations
There are different methods that can be used to diagnose
sarcopenia. In particular, the methods used for measuring
muscle mass are very diverse. In our study, we measured
muscle mass with a BIA device, as it is portable, takes
less time, and is both non-invasive and cheap. Studies
have shown that although BIA shows a good reliability
and strong correlation with DEXA, it can cause an
overestimation of SMI. BIA is also sensitive to the
hydration status, temperature, and body position of the
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participant. Furthermore, although sarcopenia is welldefined, it is still underemphasised in routine clinical
management of COPD patients. This study assessed the
prevalence of sarcopenia in a group of COPD patients
in one health centre. Further multi-centred studies are
needed to evaluate sarcopenia in larger COPD patient
groups.

precautions against loss of muscle should be taken
immediately.

6. Conclusion
In this study, dyspnoea scores and the prevalence rates of
sarcopenia were found to be higher in patients with COPD.
The existence of dyspnoea in COPD patients is due to the
loss of lung function and also to the loss of peripheral
muscle tissue. Depending on the losses of muscle mass,
a decrease in exercise capacity, diminished quality of life,
and increased mortality can be observed. Thus, a vicious
cycle in COPD patients begins after these losses of muscle
mass. To improve the quality of life, increase survival, and
reduce morbidity in patients with COPD, the necessary
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